1. Home
  2. BCDA vs GLTO Comparison

BCDA vs GLTO Comparison

Compare BCDA & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • GLTO
  • Stock Information
  • Founded
  • BCDA N/A
  • GLTO 2011
  • Country
  • BCDA United States
  • GLTO Denmark
  • Employees
  • BCDA N/A
  • GLTO N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • GLTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCDA Health Care
  • GLTO Health Care
  • Exchange
  • BCDA Nasdaq
  • GLTO Nasdaq
  • Market Cap
  • BCDA 7.9M
  • GLTO 6.5M
  • IPO Year
  • BCDA N/A
  • GLTO 2020
  • Fundamental
  • Price
  • BCDA $2.72
  • GLTO $4.58
  • Analyst Decision
  • BCDA Strong Buy
  • GLTO Buy
  • Analyst Count
  • BCDA 1
  • GLTO 1
  • Target Price
  • BCDA $25.00
  • GLTO $10.00
  • AVG Volume (30 Days)
  • BCDA 53.2K
  • GLTO 20.7K
  • Earning Date
  • BCDA 03-26-2025
  • GLTO 03-07-2025
  • Dividend Yield
  • BCDA N/A
  • GLTO N/A
  • EPS Growth
  • BCDA N/A
  • GLTO N/A
  • EPS
  • BCDA N/A
  • GLTO N/A
  • Revenue
  • BCDA $71,000.00
  • GLTO N/A
  • Revenue This Year
  • BCDA N/A
  • GLTO N/A
  • Revenue Next Year
  • BCDA N/A
  • GLTO N/A
  • P/E Ratio
  • BCDA N/A
  • GLTO N/A
  • Revenue Growth
  • BCDA N/A
  • GLTO N/A
  • 52 Week Low
  • BCDA $1.63
  • GLTO $4.24
  • 52 Week High
  • BCDA $8.85
  • GLTO $23.50
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 64.47
  • GLTO 40.37
  • Support Level
  • BCDA $2.27
  • GLTO $4.24
  • Resistance Level
  • BCDA $2.78
  • GLTO $4.65
  • Average True Range (ATR)
  • BCDA 0.28
  • GLTO 0.34
  • MACD
  • BCDA 0.03
  • GLTO -0.05
  • Stochastic Oscillator
  • BCDA 91.04
  • GLTO 25.76

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: